Celgene weakness an overreactions, says Wells Fargo Wells Fargo said Celgene weakness related to the upcoming Markman hearing and the UK's The National Institute for Health and Care Excellence guidance that thalidomide vs. Revlimid should be considered in most second line MM patients is an overreaction. The firm said the Markman hearing has been an overhang but there are many steps needed before a final outcome and that the UK's decision is not meaningful given current reimbursement is only for 3rd+ line anyway. The firm would use weakness in Celgene as a buying opportunity and reiterates its Outperform rating.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.